By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Calling Affymetrix a "turnaround story," investment firm Mizuho Securities initiated coverage of the microarray firm with an Outperform rating and a price target of $6 per share.

In a research report published Thursday, analyst Peter Lawson estimated Affy's 2011 loss per share at $.06 on revenues of $275.7 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: epigenetic changes linked with high-altitude pulmonary edema, transcriptome profiling of maize leaf development, and more.

Stanford University researchers are studying top athletes to uncover genes linked to performance.

The UW's Wylie Burke and Dartmouth's Gilbert Welch argue that whole-genome testing may do more harm than good, and a related poll.

In PLOS this week: phylogenetic study of hepatitis E viruses in Swedish moose, recombination sites in the honeybee genome, and more.